Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 3/2003

Open Access 01-06-2003 | Research article

C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer

Authors: Petr Beneš, Michal Jurajda, Jan Žaloudík, Lydie Izakovičová-Hollá, Jiří Vácha

Published in: Breast Cancer Research | Issue 3/2003

Login to get access

Abstract

Background

Low-density lipoprotein receptor-related protein 1 (LRP1) is a multifunctional endocytic receptor with an important role in regulating the activity of proteinases in extracellular matrix. Several studies have also described its role in intracellular signaling. Previous studies showed that the expression of LRP1 is related to invasiveness of cancer cells. However, recent data on LRP1 suggest that this receptor can also be involved in tumor establishment and progression.

Methods

We investigated an association between the C766T polymorphism of the third exon of the LRP1 gene and breast cancer in a sample of women of Caucasian origin. Allele and genotype frequencies of this polymorphism were assessed in 164 women with breast cancer and in 183 age-compatible women without a history of any cancer disease.

Results

An increase in LRP1 T allele frequency in subjects with breast cancer was observed compared with controls (0.21 versus 0.15, P = 0.01963). A significant excess of genotypes with the T allele (homozygotes plus heterozygotes) was also observed (odds ratio 1.743, 95% confidence interval 1.112–2.732).

Conclusion

The T allele of the C766T polymorphism in the LRP1 gene is associated with an increased risk of breast cancer development in women of Caucasian origin.
Literature
1.
Strickland DK, Kounnas MZ, Williams SE, Argraves WS: LDL receptor-related protein (LRP1): a multiligand receptor. Fibrinolysis. 1994, 8: 204-215.CrossRef
2.
Kasza A, Petersen HH, Heegaard CW, Oka K, Christensen A, Dubin A, Chan L, Andreasen PA: Specifity of serine proteinase/ serpin complex binding to very-low-density lipoprotein receptor and α2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein. Eur J Biochem. 1997, 248: 270-281.CrossRefPubMed
3.
4.
Barmina OY, Walling HW, Fiacco GJ, Freije JM, Lopez-Otin C, Jeffrey JJ, Partridge NC: Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization. J Biol Chem. 1999, 274: 30087-30093. 10.1074/jbc.274.42.30087.CrossRefPubMed
5.
Yang Z, Strickland DK, Bornstein P: Extracellular matrix metalloproteinase 2 levels are regulated by the low density lipoprotein-related scavenger receptor and thrombospondin 2. J Biol Chem. 2001, 276: 8403-8408. 10.1074/jbc.M008925200.CrossRefPubMed
6.
Li Y, Wood N, Grimsley P, Yellowlees D, Donnelly PK: In vitro invasiveness of human breast cancer cells is promoted by low density lipoprotein receptor-related protein. Invasion Metastasis. 1998, 18: 240-251. 10.1159/000024517.CrossRefPubMed
7.
Lutz C, Nimpf J, Jenny M, Boecklinger K, Enzinger C, Utermann G, Baier-Bitterlich G, Baier G: Evidence of functional modulation of the MEKK/JNK/cJun signaling cascade by the low density lipoprotein receptor-related protein (LRP1). J Biol Chem. 2002, 277: 43143-43151. 10.1074/jbc.M204426200.CrossRefPubMed
8.
van der Geer P: Phosphorylation of LRP11: regulation of transport and signal transduction. Trends Cardiovasc Med. 2002, 12: 160-165. 10.1016/S1050-1738(02)00154-8.CrossRefPubMed
9.
Binder RJ, Han DK, Srivastava PK: CD91: a receptor for heat shock protein gp96. Nat Immunol. 2000, 1: 151-155. 10.1038/77835.CrossRefPubMed
10.
Yamamoto M, Ikeda K, Oshshima K, Tsugo H, Kimura H, Tomonaga M: Increased expression of low density lipoprotein receptor-related protein/α2-macroglobulin receptor in human malignant astrocytomas. Cancer Res. 1997, 57: 2799-2805.PubMed
11.
Bu G, Maksymovitch EA, Geuze H, Schwartz AL: Subcellular localization and endocytic function of low density lipoprotein receptor-related protein in human glioblastoma cells. J Biol Chem. 1994, 269: 29874-29882.PubMed
12.
Van Leuven F, Cassiman JJ, Van den Berghe H: Demonstration of an α2-macroglobulin receptor in human fibroblasts, absent in tumor-derived cell lines. J Biol Chem. 1979, 254: 5155-5160.PubMed
13.
Saksela O, Wahström T, Lehtovirta P, Seppälä M, Vaheri A: Presence of α2-macroglobulin in normal but not in malignant syncytiotrophoblasts. Cancer Res. 1981, 41: 2507-2513.PubMed
14.
Baum L, Dong ZY, Choy KW, Pang CP, Ng HK: Low density lipoprotein receptor related protein gene amplification and 766T polymorphism in astrocytomas. Neurosci Lett. 1998, 256: 5-8. 10.1016/S0304-3940(98)00734-4.CrossRefPubMed
15.
Grimsley PG, Quinn KA, Chesterman CN, Owensby DA: Low density lipoprotein receptor-related protein (LRP1) expression varies among Hep G2 cell lines. Thromb Res. 1997, 88: 485-498. 10.1016/S0049-3848(97)00287-9.CrossRefPubMed
16.
Liu CX, Musco S, Lisitsina NM, Yaklichkin SY, Lisitsyn NA: Genomic organization of a new candidate tumor suppressor gene, LRP11B. Genomics. 2000, 69: 271-274. 10.1006/geno.2000.6331.CrossRefPubMed
17.
Langbein S, Szakacs O, Wilhelm M, Sukosd F, Weber S, Jauch A, Lopez Beltran A, Alken P, Kalble T, Kovacs G: Alteration of the LRP11B gene region is associated with high grade of urothelial cancer. Lab Invest. 2002, 82: 639-643.CrossRefPubMed
18.
Kang DE, Saitoh T, Chen X, Masliah E, Hansen LA, Thomas RG, Thal LJ, Katzman R: Genetic association of the low-density lipoprotein receptor-related protein gene (LRP1), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 1997, 49: 56-61.CrossRefPubMed
19.
Hollenbach E, Ackerman S, Hyman BT, Rebeck W: Confirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer's disease. Neurology. 1998, 50: 1905-1907.CrossRefPubMed
20.
Beneš P, Muzík J, Benedík J, Elbl L, Vašku A, Šišková L, Znojil V, Vácha J: The C766T low-density lipoprotein receptor-related protein polymorphism and coronary artery disease, plasma lipoproteins and longevity in Czech population. J Mol Med. 2001, 79: 116-120. 10.1007/s001090100196.CrossRefPubMed
21.
22.
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991, 64: 327-336.CrossRefPubMed
23.
Danø K, Andreasen PA, Grondahl-Hansen K, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 1985, 44: 139-266.CrossRefPubMed
24.
Danø K, Rømer J, Nielsen BS, Bjørn S, Pyke C, Rygaard J, Lund LR: Cancer invasion and tissue remodeling – cooperation of protease systems and cell types. APMIS. 1999, 107: 120-127.CrossRefPubMed
25.
McCawley L, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today. 2000, 6: 149-156. 10.1016/S1357-4310(00)01686-5.CrossRefPubMed
26.
Cuzner ML, Opdenakker G: Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J Neuroimmunol. 1999, 94: 1-14. 10.1016/S0165-5728(98)00241-0.CrossRefPubMed
27.
Bergers G, Coussens LM: Extrinsic regulators of epithelial tumor progression: metalloproteinases. Curr Opin Genet Dev. 2000, 10: 120-127. 10.1016/S0959-437X(99)00043-X.CrossRefPubMed
28.
Shaulian E, Karin M: AP-1 in cell proliferation and survival. Oncogene. 2001, 20: 2390-2400. 10.1038/sj.onc.1204383.CrossRefPubMed
29.
Macaluso M, Russo G, Cinti C, Bazan V, Gebbia N, Russo A: Ras family genes: an interesting link between cell cycle and cancer. J Cell Physiol. 2002, 192: 125-130. 10.1002/jcp.10109.CrossRefPubMed
30.
Barnes H, Larsen B, Tyers M, van der Geer P: Tyrosine-phosphorylated low density lipoprotein receptor-related protein 1 (LRP11) associates with the adaptor protein SHC in SRC-transformed cells. J Biol Chem. 2001, 276: 19119-19125. 10.1074/jbc.M101216200.CrossRefPubMed
31.
Koong AC, Denko NC, Hudson KM, Schindler C, Swiersz L, Koch C, Evans S, Ibrahim L, Le QT, Terris DJ, Giaccia AJ: Candidate genes for the hypoxic tumor phenotype. Cancer Res. 2000, 60: 883-887.PubMed
32.
Li Y, Wood N, Donnelly P, Yellowlees D: Cell density and oestrogen both stimulate alpha 2-macroglobulin receptor expression in breast cancer cell T-47D. Anticancer Res. 1998, 18: 1197-1202.PubMed
33.
Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G: Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol. 2002, 160: 237-246.CrossRefPubMedPubMedCentral
Metadata
Title
C766T low-density lipoprotein receptor-related protein 1 (LRP1) gene polymorphism and susceptibility to breast cancer
Authors
Petr Beneš
Michal Jurajda
Jan Žaloudík
Lydie Izakovičová-Hollá
Jiří Vácha
Publication date
01-06-2003
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2003
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr591

Other articles of this Issue 3/2003

Breast Cancer Research 3/2003 Go to the issue

Research article

Elevated mammaglobin (h-MAM) expression in breast cancer is associated with clinical and biological features defining a less aggressive tumour phenotype

Commentary

The future of cytotoxic therapy: selective cytotoxicity based on biology is the key

Editorial

Introducing Viewpoints – Breast Cancer Research'snew style literature appraisal service

Commentary

Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk

Review

The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer

Review

Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits